Erik J. van Helden
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Erik J. van Helden has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Anne Isabelle Juliette Arens
Department of Medical Imaging, Radboud University Medical Center, Nijmegen, The Netherlands
6 shared publications - Catharina Willemien Menke-Van der Houven van Oordt
Department of Medical Oncology, Amsterdam UMC Location Vrije Universiteit Amsterdam, Amsterdam, The Netherlands
6 shared publications - Derk Jan A. de Groot
Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
6 shared publications - Elske C. Gootjes
Department of Medical Oncology, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands
6 shared publications - Emma Geertruida Elisabeth de Vries
Department of Medical Oncology, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, The Netherlands
6 shared publications - Gerben J. C. Zwezerijnen
Amsterdam UMC, Amsterdam, The Netherlands
6 shared publications
Latest Publications
- Open Access
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Early [18F]FDG PET/CT Response after a Single Dose of Anti-EGFR Therapy as a Predictive Biomarker for Treatment Benefit in Patients with Advanced Colorectal Cancer
Supplementary Table 2: Mean percentage changes in volumetric and semi-quantitative FDG PET/CT parameters during treatment (baseline vs. on-treatment) Part 2
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Early [18F]FDG PET/CT Response after a Single Dose of Anti-EGFR Therapy as a Predictive Biomarker for Treatment Benefit in Patients with Advanced Colorectal Cancer
Supplementary Table 2: Mean percentage changes in volumetric and semi-quantitative FDG PET/CT parameters during treatment (baseline vs. on-treatment) Part 2
- Open Access
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Data from Early [18F]FDG PET/CT Response after a Single Dose of Anti-EGFR Therapy as a Predictive Biomarker for Treatment Benefit in Patients with Advanced Colorectal Cancer
Purpose:Anti-EGFR mAb therapy improves the clinical outcome of patients with metastatic colorectal cancer (mCRC). This study assessed the predictive value of early [18F]fluorodeoxyglucose ([18F]FDG) PET/CT after one anti-EGFR mAb treatment in patients with mCRC.Patients and Methods:The multicenter IMPACT-CRC study (NCT02117466) prospectively included patients with mCRC receiving second- or third-line anti-EGFR mAb monotherapy. Clinical benefit (complete/partial response or stable disease per RECIST version 1.1) was determined with CT at 8 weeks. [18F]FDG PET/CT scans were performed at baseline and before the second treatment cycle (2 weeks). Total lesion glycolysis (TLG) change was evaluated as a predictive biomarker for clinical benefit using a predetermined data-driven threshold.Results:In patients with RAS/BRAF wild-type left-sided mCRC, the clinical benefit rate was 92% (31% partial response, 61% stable disease), with a median progression-free survival of 5.7 months (95% CI, 5.2–10). Seventy-five patients, including those with right-sided mCRC, were eligible for metabolic response analysis. Patients with clinical benefit (n = 57) showed a mean decrease in sum TLG of 58% (SD = 19%), compared with 1.9% (SD = 36%) in those without clinical benefit (n = 18; P = 0.003). A threshold of <15% reduction in sum TLG had a 100% negative predictive value for clinical benefit. Metabolic responders exhibited longer progression-free survival than nonresponders [6.5 vs. 1.7 months (P < 0.001)].Conclusions:Selecting patients with left-sided RAS/BRAF wild-type mCRC resulted in a 92% clinical benefit rate from anti-EGFR mAb monotherapy. Early [18F]FDG PET/CT identified nonresponders with 100% accuracy, offering promising clinical utility when tumor mutational status is unavailable.
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Early [18F]FDG PET/CT Response after a Single Dose of Anti-EGFR Therapy as a Predictive Biomarker for Treatment Benefit in Patients with Advanced Colorectal Cancer
Purpose:Anti-EGFR mAb therapy improves the clinical outcome of patients with metastatic colorectal cancer (mCRC). This study assessed the predictive value of early [18F]fluorodeoxyglucose ([18F]FDG) PET/CT after one anti-EGFR mAb treatment in patients with mCRC.Patients and Methods:The multicenter IMPACT-CRC study (NCT02117466) prospectively included patients with mCRC receiving second- or third-line anti-EGFR mAb monotherapy. Clinical benefit (complete/partial response or stable disease per RECIST version 1.1) was determined with CT at 8 weeks. [18F]FDG PET/CT scans were performed at baseline and before the second treatment cycle (2 weeks). Total lesion glycolysis (TLG) change was evaluated as a predictive biomarker for clinical benefit using a predetermined data-driven threshold.Results:In patients with RAS/BRAF wild-type left-sided mCRC, the clinical benefit rate was 92% (31% partial response, 61% stable disease), with a median progression-free survival of 5.7 months (95% CI, 5.2–10). Seventy-five patients, including those with right-sided mCRC, were eligible for metabolic response analysis. Patients with clinical benefit (n = 57) showed a mean decrease in sum TLG of 58% (SD = 19%), compared with 1.9% (SD = 36%) in those without clinical benefit (n = 18; P = 0.003). A threshold of <15% reduction in sum TLG had a 100% negative predictive value for clinical benefit. Metabolic responders exhibited longer progression-free survival than nonresponders [6.5 vs. 1.7 months (P < 0.001)].Conclusions:Selecting patients with left-sided RAS/BRAF wild-type mCRC resulted in a 92% clinical benefit rate from anti-EGFR mAb monotherapy. Early [18F]FDG PET/CT identified nonresponders with 100% accuracy, offering promising clinical utility when tumor mutational status is unavailable.
- Open Access
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Early [18F]FDG PET/CT Response after a Single Dose of Anti-EGFR Therapy as a Predictive Biomarker for Treatment Benefit in Patients with Advanced Colorectal Cancer
Figure 1A: Change in sum TLG after 1 dose of anti-EGFR therapy versus PFS. Green dots indicate patients with and red dots patients without treatment benefit after CT evaluation part 1. Grey line at data driven cut-off of < -15% change in sumTLG Figure 1B ROC curve of change in sum TLG and treatment benefit part 1 (AUC 0.89) Figure 1C: Kaplan-Meier survival curve for PFS for metabolic non-responders (<15% decrease in sum TLG) versus metabolic responders (≥15% decrease in sumTLG) patients in part 1. Figure 1D: Kaplan-Meier survival curve for OS for metabolic non-responders (<15% decrease in sum TLG) versus metabolic responders (≥15% decrease in sumTLG) patients in part 1.
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Early [18F]FDG PET/CT Response after a Single Dose of Anti-EGFR Therapy as a Predictive Biomarker for Treatment Benefit in Patients with Advanced Colorectal Cancer
Figure 1A: Change in sum TLG after 1 dose of anti-EGFR therapy versus PFS. Green dots indicate patients with and red dots patients without treatment benefit after CT evaluation part 1. Grey line at data driven cut-off of < -15% change in sumTLG Figure 1B ROC curve of change in sum TLG and treatment benefit part 1 (AUC 0.89) Figure 1C: Kaplan-Meier survival curve for PFS for metabolic non-responders (<15% decrease in sum TLG) versus metabolic responders (≥15% decrease in sumTLG) patients in part 1. Figure 1D: Kaplan-Meier survival curve for OS for metabolic non-responders (<15% decrease in sum TLG) versus metabolic responders (≥15% decrease in sumTLG) patients in part 1.
- Open Access
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Early [18F]FDG PET/CT Response after a Single Dose of Anti-EGFR Therapy as a Predictive Biomarker for Treatment Benefit in Patients with Advanced Colorectal Cancer
Supplementary - Study Representativeness Table
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Early [18F]FDG PET/CT Response after a Single Dose of Anti-EGFR Therapy as a Predictive Biomarker for Treatment Benefit in Patients with Advanced Colorectal Cancer
Supplementary - Study Representativeness Table
- Open Access
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Data S1 from Early [18F]FDG PET/CT Response after a Single Dose of Anti-EGFR Therapy as a Predictive Biomarker for Treatment Benefit in Patients with Advanced Colorectal Cancer
Figure 1E Change in sum TLG after 1 dose of anti-EGFR therapy versus PFS in months. Green dots indicate patients with and red dots patients without treatment benefit after CT evaluation part 2. Grey line at data driven cut-off (part 1) of -15% change in sumTLG Figure 1F: Kaplan-Meier survival curve for PFS for metabolic non-responders (<15% decrease in sum TLG) versus metabolic responders (≥15% decrease in sumTLG) for patients in part 2. Figure 1G: Kaplan-Meier survival curve for OS for metabolic non-responders (<15% decrease in sum TLG) versus metabolic responders (≥15% decrease in sumTLG) for patients in part 2.
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data S1 from Early [18F]FDG PET/CT Response after a Single Dose of Anti-EGFR Therapy as a Predictive Biomarker for Treatment Benefit in Patients with Advanced Colorectal Cancer
Figure 1E Change in sum TLG after 1 dose of anti-EGFR therapy versus PFS in months. Green dots indicate patients with and red dots patients without treatment benefit after CT evaluation part 2. Grey line at data driven cut-off (part 1) of -15% change in sumTLG Figure 1F: Kaplan-Meier survival curve for PFS for metabolic non-responders (<15% decrease in sum TLG) versus metabolic responders (≥15% decrease in sumTLG) for patients in part 2. Figure 1G: Kaplan-Meier survival curve for OS for metabolic non-responders (<15% decrease in sum TLG) versus metabolic responders (≥15% decrease in sumTLG) for patients in part 2.
- 10 November 2025
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (1) , 118-126
Early [18F]FDG PET/CT Response after a Single Dose of Anti-EGFR Therapy as a Predictive Biomarker for Treatment Benefit in Patients with Advanced Colorectal Cancer
Purpose: Anti-EGFR mAb therapy improves the clinical outcome of patients with metastatic colorectal cancer (mCRC). This study assessed the predictive value of early [18F]fluorodeoxyglucose ([18F]FDG) PET/CT after one anti-EGFR mAb treatment in patients with mCRC. Patients and Methods: The multicenter IMPACT-CRC study (NCT02117466) prospectively included patients with mCRC receiving second- or third-line anti-EGFR mAb monotherapy. Clinical benefit (complete/partial response or stable disease per RECIST version 1.1) was determined with CT at 8 weeks. [18F]FDG PET/CT scans were performed at baseline and before the second treatment cycle (2 weeks). Total lesion glycolysis (TLG) change was evaluated as a predictive biomarker for clinical benefit using a predetermined data-driven threshold. Results: In patients with RAS/BRAF wild-type left-sided mCRC, the clinical benefit rate was 92% (31% partial response, 61% stable disease), with a median progression-free survival of 5.7 months (95% CI, 5.2–10). Seventy-five patients, including those with right-sided mCRC, were eligible for metabolic response analysis. Patients with clinical benefit (n = 57) showed a mean decrease in sum TLG of 58% (SD = 19%), compared with 1.9% (SD = 36%) in those without clinical benefit (n = 18; P = 0.003). A threshold of <15% reduction in sum TLG had a 100% negative predictive value for clinical benefit. Metabolic responders exhibited longer progression-free survival than nonresponders [6.5 vs. 1.7 months (P < 0.001)]. Conclusions: Selecting patients with left-sided RAS/BRAF wild-type mCRC resulted in a 92% clinical benefit rate from anti-EGFR mAb monotherapy. Early [18F]FDG PET/CT identified nonresponders with 100% accuracy, offering promising clinical utility when tumor mutational status is unavailable.
- 10 November 2025
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (1) , 118-126
Early [18F]FDG PET/CT Response after a Single Dose of Anti-EGFR Therapy as a Predictive Biomarker for Treatment Benefit in Patients with Advanced Colorectal Cancer
Purpose: Anti-EGFR mAb therapy improves the clinical outcome of patients with metastatic colorectal cancer (mCRC). This study assessed the predictive value of early [18F]fluorodeoxyglucose ([18F]FDG) PET/CT after one anti-EGFR mAb treatment in patients with mCRC. Patients and Methods: The multicenter IMPACT-CRC study (NCT02117466) prospectively included patients with mCRC receiving second- or third-line anti-EGFR mAb monotherapy. Clinical benefit (complete/partial response or stable disease per RECIST version 1.1) was determined with CT at 8 weeks. [18F]FDG PET/CT scans were performed at baseline and before the second treatment cycle (2 weeks). Total lesion glycolysis (TLG) change was evaluated as a predictive biomarker for clinical benefit using a predetermined data-driven threshold. Results: In patients with RAS/BRAF wild-type left-sided mCRC, the clinical benefit rate was 92% (31% partial response, 61% stable disease), with a median progression-free survival of 5.7 months (95% CI, 5.2–10). Seventy-five patients, including those with right-sided mCRC, were eligible for metabolic response analysis. Patients with clinical benefit (n = 57) showed a mean decrease in sum TLG of 58% (SD = 19%), compared with 1.9% (SD = 36%) in those without clinical benefit (n = 18; P = 0.003). A threshold of <15% reduction in sum TLG had a 100% negative predictive value for clinical benefit. Metabolic responders exhibited longer progression-free survival than nonresponders [6.5 vs. 1.7 months (P < 0.001)]. Conclusions: Selecting patients with left-sided RAS/BRAF wild-type mCRC resulted in a 92% clinical benefit rate from anti-EGFR mAb monotherapy. Early [18F]FDG PET/CT identified nonresponders with 100% accuracy, offering promising clinical utility when tumor mutational status is unavailable.